Home
Company
Our Vision
Our Leadership Team
Naronapride (ATI-7505)
About Naronapride (ATI-7505)
Mechanism of Action
Development Status
Chemistry and Manufacturing
Latest Regulatory Developments
Knowledge Center
Chronic Idiopathic Constipation
Irritable Bowel Syndrome
GERD
Functional Dyspepsia
Gastroparesis
Other Therapeutic Indications
News
Press
>
Sinovant Sciences and Renexxion Form Partnership to Develop Naronapride in China BEIJING, SHANGHAI, and Menlo Park
Renexxion Achieves Positive FDA Guidance for Phase 3 ready GI Drug Naronapride
Contact
Contact
Renexxion
325 Sharon Park Drive, #303
Menlo Park, CA 94025
Tel. No. +1 650 924 9895 / +1 650 376 0598
Fax. +1 415 449 3581
Business Development enquiries
: bd(at)renexxion(dot)com
Press and media enquiries
: press(at)renexxion(dot)com
Please replace (at) and (dot) with their respective symbols as in example@renexxion.com
*
Indicates required field
Name
*
First
Last
Email
*
Comment
*
Submit
Home
Company
Our Vision
Our Leadership Team
Naronapride (ATI-7505)
About Naronapride (ATI-7505)
Mechanism of Action
Development Status
Chemistry and Manufacturing
Latest Regulatory Developments
Knowledge Center
Chronic Idiopathic Constipation
Irritable Bowel Syndrome
GERD
Functional Dyspepsia
Gastroparesis
Other Therapeutic Indications
News
Press
>
Sinovant Sciences and Renexxion Form Partnership to Develop Naronapride in China BEIJING, SHANGHAI, and Menlo Park
Renexxion Achieves Positive FDA Guidance for Phase 3 ready GI Drug Naronapride
Contact